| 案》； | 2.《关于全资子公司重庆鸿翔一心堂药业有限公司收购重 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 庆市万州区爱一百药房 | 10 | 家门店资产及其存货的议案》； | 3.《关于全资子公司山西鸿翔一心堂药业有限公司收购山 | | | | | | | | | | | 西省鑫金牛大药房医药连锁有限公司 | 21 | 家门店资产及其 | 存货的议案》； | | | | | | | | | | | 4.《关于 | 2020 | 年限制性股票激励计划预留授予部分第三个 | 解除限售期解除限售条件成就的议案》。 | | | | | | | | | | | 1. | 《关于公司 | 2023 | 年年度报告全文及摘要的议案》； | 2. | 《关于公司 | 2024 | 年第一季度报告的议案》； | | | | | | | 3. | 《关于 | 2023 | 年度监事会工作报告的议案》； | 4. | 《关于 | 2023 | 年度总裁工作报 ...

| 报告期指标 | 2024年年报 | 2023年年报 | 本年比上年增减(%) | 2022年年报 | | --- | --- | --- | --- | --- | | 基本每股收益（元） | 0.1927 | 0.9207 | -79.07 | 1.7022 | | 每股净资产（元） | 0 | 13 | -100 | 12.46 | | 每股公积金(元) | 3.45 | 3.6 | -4.17 | 3.6 | | 每股未分配利润(元) | 7.72 | 7.80 | -1.03 | 7.27 | | 每股经营现金流(元) | - | - | - | - | | 营业收入(亿元) | 180 | 173.8 | 3.57 | 174.32 | | 净利润(亿元) | 1.14 | 5.49 | -79.23 | 10.1 | | 净资产收益率(%) | 1.50 | 6.97 | -78.48 | 14.47 | 数据四舍五入，查看更多财务数据>> 二、前10名无限售条件股东持股情况 一、主要会计数据和财务指标 前十大流通股东累计持有： 15858.06万股，累计占流通股比： 39.91%，较上期变化 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-034 号 一心堂药业集团股份有限公司 关于召开 2024 年年度股东会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一心堂药业集团股份有限公司(以下简称"公司"或"本公司")于 2025年 4 月 25 日召开 第六届董事会第十四次会议，会议决议于 2025 年 5 月 21 日下午 14 时在公司会议室召开公司 2024 年年度股东会，本次股东会采用现场投票与网络投票相结合的方式召开，现将本次会议的 有关事项通知如下： 一、召开会议的基本情况 1、股东会届次：2024 年年度股东会 2、会议召集人：公司第六届董事会 3、会议召开的合法、合规性：公司第六届董事会第十四次会议审议通过了《关于召开 2024 年年度股东会的议案》。公司董事会召集本次股东会会议符合有关法律、行政法规、部门规章、 规范性文件和《公司章程》的相关规定。 4、会议召开的日期和时间： （1）现场会议召开时间：2025 年 5 月 21 日（星期三）下午 14 点； （2）网络投票时间：2025 年 ...

一心堂药业集团股份有限公司 监事会对公司《2024年度内部控制自我评价报告》的意见 根据《深圳证券交易所股票上市规则》《深圳证券交易所上市公司自律监管 指引第1号——主板上市公司规范运作》《企业内部控制基本规范》等规章制度 的相关规定,一心堂药业集团股份有限公司（以下简称"公司"）第六届监事会 第十四次会议审议通过《关于公司2024年度内部控制自我评价报告的议案》,监 事会对公司《2024年度内部控制自我评价报告》发表意见如下： 监事会认为：公司内部控制自我评价比较客观地反映了公司内部控制的真实 情况，对公司内部控制的总结比较全面，反映了公司重点控制活动的内部控制情 况。公司根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监 管要求，遵循内部控制的基本原则，结合公司目前经营业务的实际情况及监管意 见，建立健全了涵盖公司经营管理各环节，并且适应公司管理要求和发展需要的 内部控制体系。公司各项制度自制订以来得到了有效贯彻执行，对公司的规范运 作起到了较好的监督、指导作用。报告期内，公司不存在违反内控相关法规及公 司内部控制制度的情形。监事会对《2024 年度内部控制自我评价报告》无异议。 2025 年 ...

股票代码：002727 股票简称：一心堂 公告编号：2025-023 号 一心堂药业集团股份有限公司 第六届监事会第十四次会议决议公告 一心为民 全心服务 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 一心堂药业集团股份有限公司(以下简称"公司")第六届监事会第十四次会议于 2025 年 4 月 25 日 9 时以现场及通讯表决方式在公司会议室召开，本次会议于 2025 年 4 月 14 日通过邮件 和书面形式发出通知。本次会议应出席会议的监事为 3 人，实际出席会议的监事为 3 人。本次 会议的召开符合有关法律、行政法规、部门规章、规范性文件和《公司章程》的规定。 会议由冯萍女士主持。与会监事逐项审议了有关议案并做出决议如下。 二、监事会会议审议情况 1、审议通过《关于公司 2024 年年度报告全文及摘要的议案》 经审核，监事会认为董事会编制和审议一心堂药业集团股份有限公司 2024 年年度报告的程 序符合法律、行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了公司的实际 情况，不存在任何虚假记载、误导性陈述或者重大遗漏。 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-024 号 一心堂药业集团股份有限公司 第六届董事会第十四次会议决议公告 2、审议通过《关于公司 2025 年第一季度报告的议案》 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 一心堂药业集团股份有限公司(以下简称"公司")第六届董事会第十四次会议于2025年4 月25日10时以现场及通讯表决方式在公司会议室召开，本次会议于2025年4月14日通过邮件及书 面形式发出通知。本次会议应出席会议的董事为9人，实际出席会议的董事为9人。公司监事及 非董事高级管理人员列席了会议。本次会议的召开符合有关法律、行政法规、部门规章、规范 性文件和《公司章程》的规定。会议由阮鸿献先生主持。与会董事逐项审议了有关议案并做出 决议如下。 二、董事会会议审议情况 1、审议通过《关于公司 2024 年年度报告全文及摘要的议案》 《2024 年年度报告》具体内容详见公司指定信息披露媒体巨潮资讯网 （www.cninfo.com.cn）。并批准 2024 年财务报告对外报出。 《2 ...

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-028 号 一心堂药业集团股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、审议程序 一心堂药业集团股份有限公司(以下简称"公司")于 2025 年 4 月 25 日召开第六届董事会 第十四次会议、第六届监事会第十四次会议，审议通过了《关于公司 2024 年度利润分配预案的 议案》，该议案尚需提交 2024 年年度股东会审议，现将该预案的基本情况公告如下： 二、2024 年度利润分配预案的基本情况 经中审众环会计师事务所（特殊普通合伙）出具的标准无保留意见审计报告，公司 2024 年实现归属于上市公司股东的母公司净利润为 348,485,943.92 元。依据《公司法》和《公司章 程》等有关规定，2024 年度不提取法定盈余公积金，公司拟按以下方案实施分配： A、加年初未分配利润 2,900,636,579.50 元，减本年度已分配利润 238,402,170.00 元，2024 年度可供股东分配的利润为 3,010,720 ...

Financial Performance - The company's revenue for Q1 2025 was ¥4,766,597,593.46, a decrease of 6.53% compared to ¥5,099,517,768.62 in the same period last year[5] - Net profit attributable to shareholders was ¥160,069,489.05, down 33.83% from ¥241,918,445.99 year-on-year[5] - The basic earnings per share decreased by 32.67% to ¥0.2733 from ¥0.4059 in the previous year[5] - Total operating revenue for the current period is $4.77 billion, a decrease of 6.5% from $5.10 billion in the previous period[26] - Net profit for the current period is $164.26 million, a decline of 33.3% compared to $246.31 million in the previous period[27] - Basic and diluted earnings per share decreased to $0.2733 from $0.4059, reflecting a 32.5% drop[28] Assets and Liabilities - The total assets at the end of the reporting period were ¥16,948,291,374.30, reflecting a slight increase of 0.70% from ¥16,830,316,478.61 at the end of the previous year[5] - The total current assets increased to RMB 9.99 billion from RMB 9.71 billion, with cash and cash equivalents rising to RMB 3.45 billion[22] - The total liabilities increased to RMB 9.28 billion from RMB 9.18 billion, with current liabilities accounting for RMB 7.68 billion[24] - Non-current assets decreased to RMB 6.95 billion from RMB 7.12 billion, with fixed assets valued at RMB 930.49 million[23] - The company's retained earnings increased to RMB 4.68 billion from RMB 4.52 billion, reflecting a growth in undistributed profits[24] Cash Flow - Cash flow from operating activities was ¥490,153,278.63, down 6.01% from ¥521,470,407.90 in the same period last year[5] - Net cash flow from operating activities is $490.15 million, down 6.0% from $521.47 million in the previous period[29] - Cash and cash equivalents at the end of the period totaled $1.61 billion, a decrease from $3.28 billion at the end of the previous period[30] - Cash recovered from investments increased by 499.00% to ¥1.20 billion, reflecting the recovery of principal from time deposits[13] - Cash paid for various taxes decreased by 66.98% to ¥97.79 million, primarily due to tax payments for the end of 2023[13] Investments and Financing - The company reported a significant increase in investment income of 319.29%, amounting to ¥1,397,240.69 compared to a loss of ¥637,173.05 in the previous year[12] - Cash paid for fixed assets and other long-term assets increased by 72.10% to ¥91.38 million, with ongoing projects in modern pharmaceutical logistics and digital manufacturing[13] - Cash invested in short-term time deposits surged by 33,128.57% to ¥1.16 billion[13] - Cash received from borrowings increased by 104.40% to ¥384.27 million, attributed to new stock repurchase loans[13] - The company has secured a stock repurchase loan commitment of RMB 135 million from Shanghai Pudong Development Bank for a three-year term[19] Shareholder Information - The total number of common shareholders at the end of the reporting period was 37,417[15] - The largest shareholder, Ruan Hongxian, holds 31.12% of shares, amounting to 182,245,290 shares[15] - The company has repurchased a total of 11,475,900 shares, representing 1.96% of the total share capital, with a total transaction amount of approximately RMB 149.99 million[20] - The company plans to use between RMB 80 million and RMB 150 million for share repurchase, with a maximum repurchase price set at RMB 19.02 per share[19] Operational Changes - As of March 31, 2025, the total number of stores decreased to 11,451 from 11,498, with 124 new openings and 125 closures during the period[17] - The company experienced a 47.07% decrease in tax and additional charges, totaling ¥5,478,936.82 compared to ¥10,351,529.70 last year[10] - The company’s long-term loans increased to ¥135,081,427.21 due to the addition of stock repurchase loans[9] - The company’s prepayments increased by 38.76% to ¥184,820,333.60, attributed to increased prepayments for goods by subsidiaries[9] Miscellaneous - The first quarter report of Yixin Tang Pharmaceutical Group Co., Ltd. is unaudited[31] - The new accounting standards will be implemented starting from 2025[31] - The financial statement items related to the first year of the new accounting standards will be adjusted at the beginning of the year[31] - The board of directors announced the first quarter report on April 25, 2025[31] - There are no specific performance summaries or user data provided in the document[31] - Future outlook and performance guidance are not detailed in the document[31] - No information on new products or technology development is mentioned[31] - Market expansion and mergers or acquisitions are not addressed in the document[31] - Other new strategies are not discussed in the document[31] - The document does not provide any financial figures or percentages[31]

Financial Performance - The company's operating revenue for 2024 reached ¥18,000,454,568.58, representing a 3.57% increase compared to ¥17,380,310,852.71 in 2023[22]. - The net profit attributable to shareholders for 2024 was ¥114,138,357.24, a significant decrease of 79.23% from ¥549,441,525.99 in 2023[22]. - The net cash flow from operating activities decreased by 18.66% to ¥1,720,546,717.24 in 2024, down from ¥2,115,339,452.09 in 2023[22]. - Basic earnings per share dropped to ¥0.1927 in 2024, down 79.07% from ¥0.9207 in 2023[22]. - Total assets at the end of 2024 were ¥16,830,316,478.61, reflecting a 1.10% increase from ¥16,647,375,283.89 at the end of 2023[22]. - The net assets attributable to shareholders decreased by 3.29% to ¥7,491,014,022.79 at the end of 2024, compared to ¥7,745,981,105.08 at the end of 2023[22]. - The company reported a quarterly operating revenue of ¥5,099,517,768.62 in Q1 2024, compared to ¥4,205,555,573.96 in Q1 2023[27]. - The net profit attributable to shareholders in Q1 2024 was ¥241,918,445.99, a significant increase from ¥39,986,442.91 in Q1 2023[27]. - The company received government subsidies amounting to ¥28,583,225.78 in 2024, compared to ¥25,511,731.02 in 2023[28]. Shareholder Information - The company plans to distribute a cash dividend of 3 RMB per 10 shares (including tax) to all shareholders based on the total share capital on the equity registration date for the 2024 distribution plan[5]. - As of December 31, 2024, the largest shareholder, Mr. Ruan Hongxian, holds 182,245,290 shares, accounting for 31.12% of the total shares, indicating strong control over the company's major operational decisions[19]. - The company emphasizes the importance of accurate and complete financial reporting, with all board members present for the approval of the annual report[5]. - The company has a dedicated investor relations team, ensuring effective communication with stakeholders and investors[17]. - The company’s website provides additional resources and information for investors, enhancing accessibility to corporate updates[16]. Operational Strategy - The company has not reported any changes in its main business since its listing, maintaining a consistent operational focus[19]. - The company operates under the Shenzhen Stock Exchange with the stock code 002727, reflecting its established presence in the market[16]. - The company has a registered address in Kunming, Yunnan, indicating its operational base in a strategic location for pharmaceutical distribution[16]. - The company has committed to maintaining transparency in its financial disclosures through various media outlets, including the China Securities Journal and the Securities Times[18]. - The company employs a "centralized procurement + strategic cooperation" model to reduce procurement costs and ensure stable supply[36]. - The company focuses on enhancing professional service capabilities and improving store operational efficiency to drive growth[35]. - The company aims to create a community health ecosystem by integrating pharmacy and clinic services[33]. - The company emphasizes a customer-centric approach, aiming to provide high-quality and convenient health services[34]. Market Trends and Projections - In 2024, the retail terminal drug sales scale is expected to reach CNY 574 billion, a year-on-year increase of 3.7%[32]. - The retail scale (drugs + non-drugs) is projected to be CNY 611.9 billion, a year-on-year decrease of 1.8%[32]. - The O2O scale for pharmacies is anticipated to grow by 31.3% to CNY 48.7 billion compared to 2023[32]. - The closure rate of retail pharmacies is expected to rise to 5.7%, with approximately 39,000 pharmacies projected to close in 2024[32]. - The company has been recognized as the fifth in the "Top 100 Value List" for Chinese pharmacies for 2023-2024 and second in the "Directing Power" list[34]. Quality Control and Compliance - The company maintains a strict quality control system throughout the entire product lifecycle, ensuring compliance with regulations and safeguarding product quality[48]. - The company has established a rigorous supplier evaluation mechanism to ensure the reliability of its product channels, focusing on quality and compliance[49]. - The company has implemented a proactive quality control system, sending all cooperative products for strict testing by third-party institutions, enhancing consumer confidence and driving sales growth[50]. - An internal inspection mechanism has been established to conduct unannounced checks on various operational processes, significantly improving management efficiency and reducing quality risks[51]. - The company has optimized its cold chain management system, utilizing IoT and big data technologies for real-time monitoring of temperature and humidity during storage and transportation, ensuring the safety of refrigerated medicines[52]. Investment and Growth Strategy - The company has established a comprehensive talent training system, focusing on professional, digital, and compliance training to support sustainable development[55]. - The company has successfully developed nearly 100 courses covering common diseases, enhancing employee professional knowledge and capabilities[57]. - The company has organized 17 professional knowledge and skills competitions to stimulate learning interest and enhance professional knowledge among employees[58]. - The company is committed to sustainable development through compliance training and education, aiming to establish industry benchmarks and promote a virtuous cycle in operations[60]. - The company is actively pursuing mergers and acquisitions to enhance its market presence in the pharmaceutical industry[113]. - The company is committed to expanding its product offerings and market reach through strategic investments and acquisitions[113]. Digital Transformation - The company has launched the "Xinyun Membership System," which integrates online and offline user data to enhance customer engagement and drive business growth[68]. - The digital transformation strategy includes the development of a new health service platform, providing comprehensive health services such as online consultations and medication delivery[66]. - The company aims to deepen its digital transformation and explore innovative applications driven by data and algorithms to enhance customer-centric operations[67]. - The introduction of intelligent customer service systems marks a new stage in the company's customer operation and service capabilities, contributing to multi-dimensional value creation[68]. - The company is focused on optimizing product structure and market strategies based on user behavior data accumulated through the membership system[68]. Human Resources and Management - The total number of employees at the end of the reporting period is 36,447, with 18,160 from the parent company and 18,287 from major subsidiaries[193]. - The company has a total of 57 employees with a master's degree or higher, and 3,981 with a bachelor's degree[193]. - The company's salary policy is based on labor laws and emphasizes performance-based compensation linked to economic growth and individual contributions[194]. - The company has established a performance evaluation system for senior management, linking their performance directly to their remuneration[178]. - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 6.3008 million[179]. Governance and Compliance - The company held a total of 4 shareholder meetings during the reporting period, including 1 annual meeting, ensuring all shareholders, especially minority shareholders, could exercise their rights[153]. - The board of directors consists of 9 members, including 3 independent directors, and held 9 meetings during the reporting period to optimize operational strategies and improve store efficiency[153]. - The supervisory board is composed of 3 members and conducted 9 meetings, ensuring compliance with legal regulations and protecting shareholder rights[154]. - The company has established a comprehensive information disclosure system, adhering to legal requirements to ensure timely, fair, and accurate information dissemination[154]. - The company has implemented a "Quality and Return Double Improvement" action plan, although details on its disclosure status were not provided[151].

一心为民 全心服务 股票代码：002727 股票简称：一心堂 公告编号：2025-022 号 一心堂药业集团股份有限公司 关于控股子公司四川本草堂药业有限公司 向银行申请授信额度提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 一心堂药业集团股份有限公司(以下简称"公司")本次为控股子公司四川本草堂药业有限 公司(以下简称"四川本草堂"或"债务人")提供连带责任保证方式的担保，被担保企业四川 本草堂最近一期经审计（2023年12月31日）的资产负债率超过70%，敬请投资者充分关注担保风 险。 一、担保情况概述 一心堂药业集团股份有限公司(以下简称"公司")于 2024 年 11 月 26 日召开第六届董事会 第十二次会议，于 2024 年 12 月 13 日召开 2024 年度第三次临时股东大会，审议通过《关于同 意子公司向相关银行申请综合授信额度并为其提供担保的议案》，同意公司担保下属子公司向 相关银行申请综合授信共计 13.68 亿元，用于子公司融资业务，具体额度在不超过 13.68 亿元 的金额上限内以银行授信为准，以上综合 ...